Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

Stopped Sponsors withdrew funding; preliminary efficacy data was not encouraging.

Conditions

• Non Squamous Cell Lung Cancer
• Non Small Cell Lung Cancer

Interventions

• DRUG: Docetaxel + Sorafenib

Sponsor

Francisco Robert,MD

Collaborators

• [object Object]
• [object Object]